Related Experiment Videos
Anticancer drug evaluation: continuing progress from existing methodology
1The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract:
Current methods of anticancer drug evaluation are responsible for past successes, such as the development of cisplatin and other well-established agents. Phase II trials based on meticulously measured response rates provide an excellent tool for the identification of promising compounds whose exact place in the clinic may be further clarified in subsequent, larger studies. On the same basis, the many inactive compounds may be screened out after testing them in only a handful of patients. After a period of lull, this established methodology is once more yielding important breakthroughs.
Insights
Current anticancer drug evaluation methods, particularly Phase II trials, effectively identify promising treatments by measuring response rates. This established approach is crucial for screening compounds and driving new breakthroughs in cancer therapy.
Area of Science:
- Oncology
- Clinical Pharmacology
- Drug Development
Background:
- Established methodologies have historically driven successes in anticancer drug development, exemplified by agents like cisplatin.
- Phase II clinical trials, utilizing response rate metrics, have been instrumental in identifying effective cancer therapies.
Purpose of the Study:
- To highlight the continued efficacy of current anticancer drug evaluation methods.
- To emphasize the role of Phase II trials in identifying promising drug candidates and screening inactive compounds.
Main Methods:
- Utilizing meticulously measured response rates within Phase II trials.
- Employing a systematic screening process for anticancer compounds based on patient data.
Main Results:
- Phase II trials effectively identify promising anticancer agents for further clinical clarification.
- Inactive compounds are efficiently screened out, saving resources and time.
Conclusions:
- The established methodology for anticancer drug evaluation remains a powerful tool for scientific advancement.
- Current approaches are yielding significant breakthroughs in oncology drug discovery after a period of stagnation.